Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET
Company Participants
Vishwas Seshadri - Chief Executive Officer
Joseph Vazzano - Chief Financial Officer
Brian Kevany - Chief Technical Officer, Head of Research
Greg Gin - Vice President, Investor Relations and Corporate Communications
Conference Call Participants
Maury Raycroft - Jefferies
Operator
Good morning ladies and gentlemen, thank you for standing by. Welcome to the Abeona Q1 2022 earnings call. At this time, all participants are in a listen-only mode. After management’s prepared remarks, there will be a question-and-answer session.
I would now like to turn the call over to your host, Greg Gin, VP of Investor Relations and Corporate Communications. Please go ahead.
Greg Gin
Thank you, Kelly. Good morning, everyone. I would like to welcome and thank everyone for joining us on our first quarter 2022 conference call. The press release announcing the results is available on our website at www.abeonatherapeutics.com.
On the call today with prepared remarks are Vish Seshadri, Chief Executive Officer of Abeona, and Joe Vazzano, Chief Financial Officer. After the prepared remarks, we will host a Q&A session, and we are also joined by Dr. Brian Kevany, Chief Technical Officer and Head of Research.
Before we start, I will review our Safe Harbor statement.
Remarks made during today’s call may contain projections and forward-looking statements regarding future events. Forward-looking statements are made pursuant to the Safe Harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change, and actual results may differ materially from those expressed or implied in the forward-looking statements. Various factors that could cause actual results to differ include but are not limited to those identified under the section entitled, Risk Factors in the company’s annual report on Form 10-K and other periodic reports filed by the company with the Securities and Exchange Commission. These documents are available on our website at www.abeonatherapeutics.com.
With that, I will now turn the call over to our CEO, Vish Seshadri. Vish?
Vishwas Seshadri
Thank you, Greg. Good morning, everybody, and thank you for joining us this morning.
It’s been only a few short weeks since we last spoke in late March when we announced a new strategic plan in which we reprioritize our portfolio investments to preserve capital and extend our projected cash runway into the second quarter of 2023. Since then, we have moved quickly to divest Abeona of the MPS programs.